



FY2024 Q3 YTD Earnings Results



Revenue

¥3,528.2_B

+4.5% growth at Constant Exchange Rate (CER);
+9.8% growth at Actual Exchange Rate (AER)



Core Operating Profit

¥1,006.3B

+10.1% growth at CER / +16.3% at AER.
Growth & Launch Products more than
offset LOE impact.
Cost efficiencies resulting from
efficiency program.

Core Operating
Profit Margin

28.5%

Increased 1.6pp vs
FY2023 Q3 YTD

Reported Operating
Profit

¥417.5B

Growth in Core Operating
Profit and lower impairment
of intangible assets compared
to FY2023



Continued strong
momentum of Growth &
Launch Products

47%

Share of Total Revenue

+14.6%

Growth at CER



Core Revenue

¥4,590.0B

Core Operating Profit

¥1,150.0B

Core EPS

¥507

Upgrading Management Guidance at CER

Driven by strong product momentum and OPEX Savings

Core Revenue

Low-single-digit %
increase

Core Operating Profit

Low-single-digit %
increase

Core EPS

Flat to slightly
declining



Committed to Shareholder Return

Announcing share buyback of up to

¥100.0B

Forecasted annual dividend per share

¥196 in FY2024



Multiple programs in late-stage development, with

First **3** regulatory filings

anticipated in FY2025-FY2026

Peak revenue potential* for our six late-stage pipeline programs in total: **\$10-20 billion**

* References to peak revenue potential are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue ranges represent Takeda's assessments of various possible future commercial scenarios that may or may not occur.





This presentation contains forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations. For more information about our use of forward-looking statements, including important cautionary language, see Takeda's FY2024 Q3 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>), which is hereby incorporated by reference. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating financial results in accordance with IFRS or Core (non-IFRS) financial measures for the current period using corresponding exchange rates in the same period of the previous fiscal year.

Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate ("CER") change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow are Non-IFRS measures, i.e., measures not calculated and presented in accordance with IFRS. See the financial appendix at the end of Takeda's FY2024 Q3 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>) for further information about Takeda's Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.